Volume 7.42 | Oct 29 - Mammary Cell News

Mammary Cell News 7.42 October 29, 2015

TOP STORY

IRAK1 Is a Therapeutic Target that Drives Breast Cancer Metastasis and Resistance to Paclitaxel
Scientists report that interleukin-1 receptor-associated kinase 1 (IRAK1) is overexpressed in a subset of breast cancers, in particular triple-negative breast cancer, where it acts to drive aggressive growth, metastasis and acquired resistance to paclitaxel treatment. [Nat Commun] Full Article

Protocol and Data: Serum-Free, 3D Suspension Assay for Breast Cancer Cells

PUBLICATIONS (Ranked by impact factor of the journal)

LABORATORY RESEARCH

Stem and Progenitor Cell Division Kinetics during Postnatal Mouse Mammary Gland Development
The cycling properties of mammary stem and progenitor cells is not well understood. To determine the division properties of these cells, researchers administered synthetic nucleosides for varying periods of time to mice at different stages of postnatal development and monitored the rate of uptake of these nucleosides in the different mammary cell compartments. [Nat Commun] Full Article

FOXC1 Activates Smoothened-Independent Hedgehog Signaling in Basal-Like Breast Cancer
Investigators demonstrated that FOXC1 controls cancer stem cell properties enriched in basal-like breast cancer cells via activation of Smoothened-independent Hedgehog signaling. [Cell Rep]
Full Article | Graphical Abstract

Honokiol Sensitizes Breast Cancer Cells to TNFα Induction of Apoptosis by Inhibiting Nur77 Expression
Investigators aimed to determine whether and how Nur77 serves to mediate the effect of the inflammatory cytokine tumor necrosis factor-alpha (TNFα) in cancer cells and to identify and characterize new agents targeting Nur77 for cancer therapy. [Br J Pharmacol] Abstract

Knockdown of miR-221 Promotes the Cisplatin-Inducing Apoptosis by Targeting the BIM-Bax/Bak Axis in Breast Cancer
The authors indicated that although an anti-miR-221 oligonucleotide alone did not influence the viability of breast cancer (BC) cell lines markedly, it significantly promoted the cytotoxicity of cisplatin to BC cells. [Tumor Biol] Abstract

The Unique Transcriptional Response Produced by Concurrent Estrogen and Progesterone Treatment in Breast Cancer Cells Results in Upregulation of Growth Factor Pathways and Switching from a Luminal A to a Basal-Like Subtype
Scientists contrasted progesterone receptor function in estrogen pretreated ZR-75-1 breast cancer cells with vehicle treated ZR-75-1 and T-47D breast cancer cells using expression microarrays and chromatin immunoprecipitation-sequencing. [BMC Cancer] Full Article

MiR-33a Suppresses Breast Cancer Cell Proliferation and Metastasis by Targeting ADAM9 and ROS1
Investigators found that downregulated microRNA (miR)-33a in breast cancer tissues correlates with lymph node metastasis. MiR-33a expression is significantly lower in the highly metastatic breast cancer cell lines than the noncancerous breast epithelial cells and non-metastatic breast cancer cells. [Protein Cell] Full Article

Choline Kinase-α Protein and Phosphatidylcholine but not Phosphocholine Are Required for Breast Cancer Cell Survival
The authors used triple negative MDA-MB-231 and SUM149 breast cancer cells to investigate the role of choline kinase-α (Chk-α) in cancer, by examining Chk-α protein levels, cell viability/proliferation, choline phospholipid and lipid metabolism, lipid droplet formation, and apoptosis, following treatment with V-11-0711. [NMR Biomed] Abstract

GATA6 Is Overexpressed in Breast Cancer and Promotes Breast Cancer Cell Epithelial-Mesenchymal Transition by Upregulating Slug Expression
The authors showed that GATA6 is elevated in breast cancer (BC) and its expression level is positively correlated with metastasis. Overexpression of GATA6 in BC cells increased epithelial-mesenchymal transition. [Exp Mol Pathol] Abstract

Breast Cancer Cell Adhesome and Degradome Interact to Drive Metastasis
The authors compared non-metastatic and metastatic human breast cancer cell lines and xenografts, in which they measured growth rate, migration, invasion, colony formation, protein expression, and enzyme activity in vitro and in vivo. [npj Breast Cancer] Full Article

CLINICAL RESEARCH

Abiraterone Acetate, Exemestane or the Combination in Post-Menopausal Patients with Estrogen Receptor–Positive Metastatic Breast Cancer
Researchers assessed whether combined inhibition of androgen biosynthesis with abiraterone acetate plus prednisone and estradiol synthesis with exemestane may be of clinical benefit to postmenopausal patients with nonsteroidal aromatase inhibitor-pretreated estrogen receptor–positive metastatic breast cancer. [Ann Oncol] Abstract | Full Article

Efficacy and Safety of Bevacizumab Combined with Chemotherapy for Managing Metastatic Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
Although the FDA revoked metastatic breast cancer (MBC) from bevacizumab (BEV) indication in 2011, BEV combined with paclitaxel has been written in the breast cancer NCCN guidelines. The authors evaluated the efficacy and safety of BEV+chemotherapy for managing MBC. [Sci Rep] Full Article

Culture and Characterize Human Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Human) Free Protocols

REVIEWS

Advances in Small-Molecule Drug Discovery for Triple-Negative Breast Cancer
The authors highlight recent therapeutic advances in triple-negative breast cancer, focusing on small-molecule drugs and their associated biological mechanisms of action, and offering the possibility of improved prospects for this patient group in the near future. [Future Med Chem] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

INDUSTRY NEWS

NIH Awards City of Hope $4.8 Million Grant to Study Environment and Breast Cancer
The National Institutes of Health has awarded City of Hope a five-year, $4.8 million grant to study the possible role of chemicals in the environment in the development of breast cancer during the menopausal transition in women. [City of Hope] Press Release

Tyme Technologies, Inc. Receives FDA Acceptance of Investigational New Drug Application for Oncology Drug Candidate, SM-88
Tyme Technologies, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s investigational new drug application for SM-88, its breast cancer drug candidate. [Tyme Technologies, Inc. (Business Wire)] Press Release

OncoSec Enrolls First Patient in Biomarker-Focused Pilot Study in Triple Negative Breast Cancer
OncoSec Medical Incorporated announced that the company has enrolled the first patient into a pilot biomarker trial of ImmunoPulse™ IL-12 in patients with triple negative breast cancer. [OncoSec Medical Incorporated] Press Release

From our sponsor: 3D intestinal organoid culture is made easy with IntestiCult™. Request a sample.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW European Society for Medical Oncology (ESMO) Asia 2015 Congress
December 18-21, 2015
Singapore, Singapore

Visit our events page to see a complete list of events in the mammary cell community.

JOB OPPORTUNITIES

NEW Group Leader Position – Cancer Research (Oslo University Hospital)

Higher Scientific Officer – Breast Cancer Research (Institute of Cancer Research)

Postdoctoral Fellow – Metastatic Breast Cancer (Purdue University Center for Cancer Research)

Biological Imaging Scientist – 3D Cellular Models of Organs and Disease (University of Pittsburgh Drug Discovery Institute)

Postdoctoral Fellow – Tumor Dormancy (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Scientist – Breast Cancer (Cancer Research UK Beatson Institute)

Postdoctoral Fellow – Breast Cancer Research (University Health Network)

Research Scientist – Epithelial Stem Cells (A*STAR)

Postdoctoral Fellowship – Cancer Biology (Massachusetts General Hospital Cancer Center/Harvard Medical School)

Postdoctoral Research Fellow – Metastatic Breast Cancer (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Mammary Cell News: Archives | Events | Contact Us